Mode
Text Size
Log in / Sign up
N/A Completed N=107

Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy

Arthritis, Psoriatic, Psoriasis
Source: ClinicalTrials.gov NCT00303186 ↗
Enrolled (actual)
107
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Mean Cost Per Participant Per Month at Month 12 — 1026.32; 970.14; 4.14; 13.60 Euro/participant-month

Summary

The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. The secondary outcomes are to assess efficacy, safety, and cost effectiveness of different therapies.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Cost Per Participant Per Month at Month 12
1026.32; 970.14; 4.14; 13.60; 11.32; 27.11 —
PRIMARY
Mean Cost Per Participant Per Month at Month 60
986.34; 946.70; 16.97; 8.55; 2.58; 11.55 —
PRIMARY
Incremental Cost-effectiveness Ratio (ICER)
39678.6 —
SECONDARY
Number of Participants With Assessment in Ankylosing Spondylitis (ASAS) 20 Response
75; 37 —
SECONDARY
Number of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
86; 38 —
SECONDARY
Psoriasis Area and Severity Index (PASI)
5.04; 1.29; 2.08 <0.0001 sig
SECONDARY
Bath Ankylosing Spondylitis Functional Index (BASFI)
43.37; 25.65; 22.46 <0.0001 sig
SECONDARY
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
5.95; 3.23; 3.34 <0.0001 sig
SECONDARY
Bath Ankylosing Spondylitis Radiology Index (BASRI)
— —
SECONDARY
Modified Schober's Test
10.65; NA; 5.91 0.004 sig
SECONDARY
Chest Expansion Measurement
4.38; NA; 10.85 0.015 sig
SECONDARY
Occiput-to-wall Distance
7.02; NA; 6.24 0.676
SECONDARY
Maastricht Ankylosing Spondylitis Enthesis Score (MASES)
3.65; 2.17; 1.43 <0.0001 sig
SECONDARY
Number of Swollen and Tender Joints
7.60; 16.97; 1.26; 7.97; 0.96; 5.49 <0.0001 sig
SECONDARY
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
62.6; 70.6 —
SECONDARY
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
41.5; 43.1 —
SECONDARY
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
19.8; 26.9 —
SECONDARY
Radiographic Score Based on Wassenberg
13.58; 11.66; 28.29 0.330
SECONDARY
Patient Global Assessment (PtGA) of Disease Activity Score
63.51; 32.07; 33.16 <0.0001 sig
SECONDARY
Physician Global Assessment (PGA) of Disease Activity
60.15; 26.43; 23.00 <0.0001 sig
SECONDARY
Visual Analogue Scale for Pain (VAS-pain)
62.83; 31.39; 31.92 <0.0001 sig
SECONDARY
Erythrocyte Sedimentation Rate (ESR)
42.07; 16.36; 16.61 <0.0001 sig
SECONDARY
C-reactive Protein (CRP)
59.41; 42.07; 2.30 <0.0005 sig
SECONDARY
Duration of Morning Stiffness
— —
SECONDARY
Health Assessment Questionnaire (HAQ)
1.14; 0.71; 0.65 <0.0001 sig
SECONDARY
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score
0.38; 0.63; 0.63 <0.0001 sig
SECONDARY
Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)
46.91; 66.76; 64.17 <0.0001 sig
SECONDARY
36-Item Short-Form Health Survey (SF-36)
31.88; 40.80; 40.44; 39.15; 40.77; 45.03 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Eighteen years of age or older
  • Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA
  • Patients with diagnosis of active and progressive PsA who have failure with conventional treatments

Exclusion Criteria

  • Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00303186). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search